Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent

doi:10.1093/neuonc/noaa106

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.

Authors

Patrick Y Wen¹, Michael Weller², Eudocia Quant Lee¹, Brian M Alexander¹, Jill S Barnholtz-Sloan³, Floris P Barthel⁴, Tracy T Batchelor⁵, Ranjit S Bindra⁶, Susan M Chang⁷, E Antonio Chiocca⁸, Timothy F Cloughesy⁹, John F DeGroot¹⁰, Evanthia Galanis¹¹, Mark R Gilbert¹², Monika E Hegi¹³, Craig Horbinski¹⁴, Raymond Y Huang¹⁵, Andrew B Lassman¹⁶, Emilie Le Rhun¹⁷, Michael Lim¹⁸, Minesh P Mehta¹⁹, Ingo K Mellinghoff²⁰, Giuseppe Minniti²¹, David Nathanson²², Michael Platten²³, Matthias Preusser²⁴, Patrick Roth², Marc Sanson²⁵, David Schiff²⁶, Susan C Short²⁷, Martin J B Taphoorn²⁸, Joerg-Christian Tonn²⁹, Jonathan Tsang²², Roel G W Verhaak⁴, Andreas von Deimling³⁰, Wolfgang Wick³¹, Gelareh Zadeh³², David A Reardon¹, Kenneth D Aldape³³, Martin J van den Bent³⁴

Affiliations

¹ Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
³ Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA.
⁴ The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
⁵ Department of Neurology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School.
⁶ Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.
⁷ University of California San Francisco, San Francisco, California, USA.
⁸ Department of Neurosurgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
⁹ David Geffen School of Medicine, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
¹⁰ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
¹¹ Mayo Clinic, Rochester, Minnesota, USA.
¹² Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
¹³ Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
¹⁴ Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
¹⁵ Division of Neuroradiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
¹⁶ Department of Neurology and Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
¹⁷ University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
¹⁸ Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁹ Miami Cancer Institute, Miami, Florida, USA.
²⁰ Department of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²¹ Radiation Oncology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
²² Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, USA.
²³ Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany.
²⁴ Division of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.
²⁵ Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
²⁶ University of Virginia School of Medicine, Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
²⁷ Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
²⁸ Department of Neurology, Medical Center Haaglanden, The Hague and Department of Neurology, Leiden University Medical Center, the Netherlands.
²⁹ Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
³⁰ Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany.
³¹ Department of Neurology and Neuro-oncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
³² MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Canada.
³³ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
³⁴ Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Abstract

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

Keywords: clinical trials; diagnosis; glioblastoma; therapy.

Publication types

Review

MeSH terms

Brain Neoplasms* / enzymology
Brain Neoplasms* / genetics
Brain Neoplasms* / therapy
Chemoradiotherapy
Clinical Trials, Phase III as Topic
Consensus
Glioblastoma* / enzymology
Glioblastoma* / genetics
Glioblastoma* / therapy
Humans
Isocitrate Dehydrogenase / genetics
Isocitrate Dehydrogenase / metabolism
Randomized Controlled Trials as Topic

Substances

Isocitrate Dehydrogenase

Abstract

Publication types

MeSH terms

Substances

Grants and funding